FT-671

Research use only, not for human use.

FT-671 is a novel potent, specific, non-covalent USP7 inhibitor with Kd of 65 nM (USP7 catalytic domain).

FT-671 is a novel potent, specific, non-covalent USP7 inhibitor with Kd of 65 nM (USP7 catalytic domain); inhibits USP7 with IC50 values of 52 nM (USP7 CD) and 69 nM (USP7C-term), display good USP7 selectivity in a panel of 38 deubiquitinases (DUBs); destabilizes USP7 substrates including MDM2, increases levels of p53, and results in the transcription of p53 target genes and induces tumour suppressor p21; blocks the proliferation of MM.1S cells (IC50=33 nM), suppresses tumour growth in mice; orally available.

——

——

FT671 | FT 671

Proteasome/Ubiquitin

DUB

DUB

Cancer

——

1959551-26-8

533.488

C24H23F4N7O3

>98% (HPLC)

——

O=C1C2=C(N=CN1CC3(CCN(CC3)C(C[C@@H](C(F)F)N4N=C(C=C4)F)=O)O)N(N=C2)C5=CC=C(C=C5)F

(S)-5-((1-(4,4-difluoro-3-(3-fluoro-1H-pyrazol-1-yl)butanoyl)-4-hydroxypiperidin-4-yl)methyl)-1-(4-fluorophenyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one

(-20℃)

With Ice Pack

≥ 2 years